Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APT-TBI-01: Adaptive Platform Trial for Acute Traumatic Brain Injury
NCT05826912Phase 2Enrolling by invitation
- Sponsor
- University of California, San Francisco
- Start
- Aug 2024
- Primary completion
- Aug 2028
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atorvastatin, minocycline and candesartan in traumatic brain injury (TBI) (4 arms), sponsored by University of California, San Francisco. Primary endpoint: Glasgow Outcome Scale-Extended at 3 months. Started Aug 2024; status: enrolling by invitation.
02
Drugs
atorvastatinminocyclinecandesartan
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT05826912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05826912.